ATHERSYS EXTENDS PARTNERSHIP WITH BRISTOL-MYERS SQUIBB TO PROVIDE DRUG TARGETS
Athersys Inc. announced today that it has extended its existing alliance with
Bristol-Myers Squibb Company (NYSE: BMY - News) to apply its patented RAGE technology
to provide Bristol-Myers Squibb with additional validated drug targets for high-throughput
screening and lead optimization in multiple therapeutic areas. The new agreement
will extend the alliance for up to three years with a guaranteed minimum number
of targets to be supplied by Athersys annually.